HealthEquity, Inc. $HQY Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC trimmed its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY) by 3.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,536 shares of the company’s stock after selling 660 shares during the quarter. Los Angeles Capital Management LLC’s holdings in HealthEquity were worth $1,837,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD raised its stake in shares of HealthEquity by 995.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 639,345 shares of the company’s stock valued at $56,500,000 after acquiring an additional 580,988 shares during the period. Ashford Capital Management Inc. increased its holdings in HealthEquity by 2.1% in the 1st quarter. Ashford Capital Management Inc. now owns 274,999 shares of the company’s stock valued at $24,302,000 after purchasing an additional 5,687 shares during the last quarter. Comerica Bank raised its position in HealthEquity by 43.4% in the first quarter. Comerica Bank now owns 70,153 shares of the company’s stock valued at $6,199,000 after purchasing an additional 21,238 shares during the period. Axiom Investors LLC DE purchased a new stake in HealthEquity in the first quarter valued at approximately $8,276,000. Finally, CW Advisors LLC acquired a new position in HealthEquity during the first quarter worth $289,000. 99.55% of the stock is currently owned by hedge funds and other institutional investors.

HealthEquity Price Performance

Shares of HQY stock opened at $99.83 on Wednesday. The firm has a fifty day simple moving average of $93.68 and a 200-day simple moving average of $95.75. The company has a market capitalization of $8.60 billion, a PE ratio of 60.50, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47. HealthEquity, Inc. has a twelve month low of $74.07 and a twelve month high of $116.65. The company has a current ratio of 4.23, a quick ratio of 4.23 and a debt-to-equity ratio of 0.47.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings data on Tuesday, September 2nd. The company reported $0.92 EPS for the quarter, hitting analysts’ consensus estimates of $0.92. HealthEquity had a net margin of 11.49% and a return on equity of 12.04%. The firm had revenue of $325.80 million for the quarter, compared to analyst estimates of $320.68 million. HealthEquity has set its FY 2026 guidance at 3.740-3.91 EPS. Equities research analysts anticipate that HealthEquity, Inc. will post 2.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other HealthEquity news, EVP Delano Ladd sold 6,000 shares of the firm’s stock in a transaction on Friday, September 19th. The shares were sold at an average price of $94.11, for a total transaction of $564,660.00. Following the completion of the transaction, the executive vice president directly owned 79,456 shares of the company’s stock, valued at $7,477,604.16. This trade represents a 7.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Henry Fiore sold 1,781 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $88.21, for a total value of $157,102.01. Following the sale, the executive vice president owned 49,795 shares in the company, valued at $4,392,416.95. The trade was a 3.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 9,281 shares of company stock worth $859,867 over the last quarter. 1.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on HQY. Barrington Research reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of HealthEquity in a research note on Friday, August 29th. JPMorgan Chase & Co. upped their price target on HealthEquity from $125.00 to $126.00 and gave the stock an “overweight” rating in a report on Wednesday, September 3rd. Royal Bank Of Canada boosted their target price on HealthEquity from $109.00 to $110.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 3rd. Weiss Ratings reissued a “hold (c+)” rating on shares of HealthEquity in a report on Wednesday, October 8th. Finally, Jefferies Financial Group upped their price objective on HealthEquity from $130.00 to $134.00 and gave the company a “buy” rating in a research note on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, HealthEquity currently has a consensus rating of “Moderate Buy” and an average price target of $121.31.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.